AMBI

Ambipar Emergency Response Inc. (AMBI) | Rumor.io

Ambipar Emergency Response

AMBI

Attention (50-day avg)0%

Attention rank (50-day avg)#4,809

Bullish sentiment (50-day avg)100%

Price to earnings ratio34.3

Market capitalization3.9M

Earnings per share-0.01

Dividend yield (TTM)—

Revenue (annual)584.7M

Net income (annual)10.6M

Social

What share of all stock conversation is about AMBI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Oct 23

Ambipar Emergency Response (AMBI) has filed for Chapter 11 bankruptcy protection with the United States Bankruptcy Court for the Southern District of Texas.
The company is facing delisting proceedings from the NYSE American exchange.
AMBI's stock price has surged 58.23% and 61.71% on certain days, but the posts do not provide context on the reason for these price movements.

Generated by AI

Sentiment

Of the messages about AMBI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	84.53% +11.52
Bearish	—	—	—	15.47% -11.52

Bullish· Oct 1

$AMBI has shown unusual volume, breaking past resistance and screaming an oversold signal, indicating strong momentum and growth potential.
The stock has a strong momentum and growth potential, making it a positive short-term investment opportunity, despite limited quality.
$AMBI is moving above the VWAP, reclaiming the $1.20s with strong volume, and riding the 9 EMA up, indicating a potential continuation of its upward momentum.

Bearish· Mar 21

$AMBI is likely to experience a significant price drop due to a potential halt.
The stock's uptrend line was broken, indicating a reversal in the company's fortunes.
A 50% dip in value is predicted, making it a high-risk investment for traders.

Generated by AI

Topics

Of the messages about AMBI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	49.24%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.3%
Macro	0%	0%	0%	20.06%
Technical Analysis	0%	0%	0%	30.4%

Sep 29

Daiichi Sankyo is acquiring Ambit Biosciences for up to $410 million, gaining quizartinib and other oncology assets.
The deal price is $15 per share, plus potential milestones, with Ambit Biosciences going private as a result.
The acquisition is expected to bring significant value to Daiichi Sankyo's oncology pipeline, with quizartinib already in Phase III trials for acute myeloid leukemia.

Generated by AI

Community

Of the messages about AMBI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	8.67%
Newcomers	100%	100%	100%	91.33%

Regulars· Sep 29

Ambit Biosciences Corp has been acquired by Daiichi Sankyo for $15 per share in cash through a tender offer, with potential milestones adding up to $410M.
The acquisition is seen as a positive development for Ambit Biosciences, with several analysts and investors congratulating the company on the deal.
Ambit Biosciences Corp's stock has seen significant price movements, with a 86.5% increase to $15.29, and several law firms are investigating potential claims on behalf of the company's shareholders.

Newcomers· Oct 1

This newcomer is focused on the potential for short-term gains in AMBI stock due to its strong momentum and growth potential, despite limited quality.
AMBI's significant market activity and strong momentum are drawing attention from this newcomer, who is considering the stock's potential for a breakout.
This newcomer is highlighting AMBI's cash reserves ($84M) and low float (1M shares) as factors that could contribute to the stock's value and volatility.

Generated by AI

Also Discussed

Investors talking about AMBI also mention

#	Name	Attention
1	Movella Holdings Inc.MVLA	0%0
2	HPX - HPX Corp.	——
3	Moolec Science SAMLEC	0%new
4	SunCar Technology Group Inc. Class A Ordinary SharesSDA	0%0
5	Zura Bio LimitedZURA	0%new
6	SMIH - Summit Healthcare Acquisition Corp.	——
7	UHG - United Homes Group, Inc.	——
8	AEHA - Aesther Healthcare Acquisition Corp.	——
9	EBAC - European Biotech Acquisition Corp.	——
10	Apollomics Inc.APLM	0%0

Ambipar Emergency Response Inc.

Industrials
Waste Management

Ambipar Emergency Response Inc. is a vital player in the environmental services sector, specializing in emergency response and environmental management. The company's core purpose is to provide efficient and effective solutions during environmental emergencies, aiding in the containment and remediation of hazardous materials and oil spill incidents. Operating across diverse industries such as transportation, oil and gas, and petrochemicals, Ambipar Emergency Response serves a critical role in managing environmental risks and minimizing damage from industrial accidents. Its contributions are essential for industrial entities seeking compliance with environmental regulations and for safeguarding ecological and human health. With global reach and a commitment to sustainability, Ambipar Emergency Response Inc. bolsters its market significance by providing rapid response capabilities, extensive expertise, and innovative remediation technologies, making it an indispensable partner in maintaining environmental safety and stability.

Website

Location

Avenida AngElica, no 2346

São Paulo, SP, 01228-200

Brazil

Social

What share of all stock conversation is about AMBI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Oct 23

Ambipar Emergency Response (AMBI) has filed for Chapter 11 bankruptcy protection with the United States Bankruptcy Court for the Southern District of Texas.
The company is facing delisting proceedings from the NYSE American exchange.
AMBI's stock price has surged 58.23% and 61.71% on certain days, but the posts do not provide context on the reason for these price movements.

Generated by AI

Sentiment

Of the messages about AMBI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	84.53% +11.52
Bearish	—	—	—	15.47% -11.52

Bullish· Oct 1

$AMBI has shown unusual volume, breaking past resistance and screaming an oversold signal, indicating strong momentum and growth potential.
The stock has a strong momentum and growth potential, making it a positive short-term investment opportunity, despite limited quality.
$AMBI is moving above the VWAP, reclaiming the $1.20s with strong volume, and riding the 9 EMA up, indicating a potential continuation of its upward momentum.

Bearish· Mar 21

$AMBI is likely to experience a significant price drop due to a potential halt.
The stock's uptrend line was broken, indicating a reversal in the company's fortunes.
A 50% dip in value is predicted, making it a high-risk investment for traders.

Generated by AI

Topics

Of the messages about AMBI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	49.24%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.3%
Macro	0%	0%	0%	20.06%
Technical Analysis	0%	0%	0%	30.4%

Sep 29

Daiichi Sankyo is acquiring Ambit Biosciences for up to $410 million, gaining quizartinib and other oncology assets.
The deal price is $15 per share, plus potential milestones, with Ambit Biosciences going private as a result.
The acquisition is expected to bring significant value to Daiichi Sankyo's oncology pipeline, with quizartinib already in Phase III trials for acute myeloid leukemia.

Generated by AI

Community

Of the messages about AMBI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	8.67%
Newcomers	100%	100%	100%	91.33%

Regulars· Sep 29

Ambit Biosciences Corp has been acquired by Daiichi Sankyo for $15 per share in cash through a tender offer, with potential milestones adding up to $410M.
The acquisition is seen as a positive development for Ambit Biosciences, with several analysts and investors congratulating the company on the deal.
Ambit Biosciences Corp's stock has seen significant price movements, with a 86.5% increase to $15.29, and several law firms are investigating potential claims on behalf of the company's shareholders.

Newcomers· Oct 1

This newcomer is focused on the potential for short-term gains in AMBI stock due to its strong momentum and growth potential, despite limited quality.
AMBI's significant market activity and strong momentum are drawing attention from this newcomer, who is considering the stock's potential for a breakout.
This newcomer is highlighting AMBI's cash reserves ($84M) and low float (1M shares) as factors that could contribute to the stock's value and volatility.

Generated by AI

Ambipar Emergency Response

Social

Oct 23

Sentiment

Bullish· Oct 1

Bearish· Mar 21

Topics

Sep 29

Community

Regulars· Sep 29

Newcomers· Oct 1

Also Discussed

Ambipar Emergency Response Inc.

Company Information

Location

Also Discussed

Social

Oct 23

Sentiment

Bullish· Oct 1

Bearish· Mar 21

Topics

Sep 29

Community

Regulars· Sep 29

Newcomers· Oct 1